Vaccitech (NASDAQ:VACC) Third Quarter 2022 Results
Key Financial Results
Revenue: US$6.17m (up by US$6.15m from 3Q 2021).
Net income: US$8.24m (up from US$4.56m loss in 3Q 2021).
EPS: US$0.22 (up from US$0.13 loss in 3Q 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Vaccitech EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 23%. Earnings per share (EPS) exceeded analyst estimates.
Looking ahead, revenue is expected to decline by 75% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 14%.
The company's shares are down 13% from a week ago.
Before you take the next step you should know about the 5 warning signs for Vaccitech (2 can't be ignored!) that we have uncovered.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here